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Approximately 75%–80% of patients with Congenital Adrenal Hyperplasia (CAH) fail to synthesize suﬃcient mineralocorticoids
tomaintainsaltandwater balance. Inmostinstances genotypecan predictmineralocorticoid deﬁciency inCAH.Earlyrecognition
and replacement with 9α-ﬂudrocortisone and salt supplements will prevent development of potentially lethal salt losing crises. In
infancy a relative state of aldosterone resistance exists and replacement dose of 9α-ﬂudrocortisone based on body surface area is
higher during infancy compared to childhood and adults. Salt supplementation is generally not required after weaning is started.
Regular monitoring of blood pressure and measurements of plasma electrolytes and renin are required to prevent complications
of under or over dosage.
1.Introduction
Congenital adrenal hyperplasia (CAH) is a disorder of
steroidogenesis in which cortisol metabolism primarily is
impaired. Mineralocorticoid deﬁciency in CAH is a feature
of 21-Hydroxylase (21-OHD), 3β-Hydroxysteroid dehydro-
genase(3β-HSD)deﬁcienciesandlipoidadrenalhyperplasia.
Deﬁciency of 21-OHD accounts for 90% of cases of CAH [1]
while deﬁciency of 3β-HSD, and lipoid adrenal hyperplasia
are rare causes of CAH. Approximately 75% of cases of 21-
OHD [1] and 60%–70% of cases of 3β-HSD deﬁciency [2]
cannot synthesise suﬃcient aldosterone and are classed as
“salt wasters.”
2. Genotype-PhenotypeCorrelation of
Aldosterone Deﬁciency
Several studies have demonstrated strong genetic association
between the degree of mineralocorticoid and glucocorticoid
deﬁciency in 21-OHD CAH and abnormalities in the CYP21
gene [3–6]. Large gene deletions and point mutations which
are expected to produce no measurable enzyme activity
are associated with aldosterone deﬁciency and salt-wasting
21-OHD [7]. Exceptions however exist and a similar muta-
tion can be associated with more than one phenotype giving
rise to genotype-phenotype discordance [5]. The I172N
CYP21 mutation is mainly associated with simple virilizing
CAH but can also cause salt wasting CAH [8]. A signiﬁcant
diﬀerence exists between the degree of genotype-phenotype
correlation demonstrated in relation to the concentration
of aldosterone and that of genital phenotype [9]. The
relationship with degree of virilization with genotype and
aldosterone concentration is less predictable as various
genetic factors regulate androgen biosynthesis and sensitiv-
ity or the ability to retain sodium through extra-adrenal
mechanisms [9, 10]. A degree and spectrum of aldosterone
deﬁciency and salt loss exists in all forms of CAH including
those with simple virilising and nonclassical forms of CAH
[2, 11, 12]. In clinical practice this is only relevant in very hot
countries where extreme salt deprivation can manifest.
Glucocorticoids are essential for development and func-
tion of adrenal medulla and adrenomedullary function is
compromised in CAH [13]. Plasma metanephrine con-
centration is signiﬁcantly low in severe salt wasting CAH2 International Journal of Pediatric Endocrinology
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Figure 1: Aldosterone biosynthesis through renin-angiotensin
system.
compared to simple virilizing form of CAH and is compa-
rable to genotype in predicting aldosterone deﬁciency [14].
Combination of plasma metanephrine and genotype can
increase the predictability of phenotype in CAH.
Genotype phenotype association is much stronger in
patients with 3β-HSD deﬁciency with most studies demon-
strating more precise relationship with genotype and activity
of aldosterone [15].
3. Aldosterone Biosynthesis andPhysiological
Role inSaltandWaterBalance (Figure1)
Aldosterone is synthesized in the zona glomerulosa of the
adrenal cortex from corticosterone by aldosterone synthetase
(CYP11B2). The rate of aldosterone synthesis is 100–1000
fold less than cortisol. While cortisol circulates in the
serum in nanomolar concentration, the concentration of
aldosterone is 1000-fold less. Aldosterone secretion is mainly
regulated by serum potassium and angiotensin II, with
ACTH having only a short term eﬀect [15].
Renin is secreted by the juxtaglomerular apparatus in
responsetodecreasedintravascularvolume(Figure 1).Renin
cleaves angiotensinogen into angiotensin I. Angiotensin-
converting enzyme in the lungs cleaves angiotensin I to
angiotensin II, a potent vasopressor agent. Angiotensin II
acts through the angiotensin II receptor to hydrolyze phos-
phatidylinositol bisphosphate to inositol triphosphate and
diacylglycerol. These raise intracellular calcium concentra-
tions and activate protein kinase C and calmodulin-activated
(CaM) kinases. Increased concentration of extracellular
potassium depolarizes the cell membrane and increases
calcium inﬂux through voltage-gated calcium channels
which similarly activate protein kinase C and calmodulin-
activated (CaM) kinases. Phosphorylation of transcriptional
regulatory factors by CaM kinases increases transcription
of the aldosterone synthase (CYP11B2) gene required for
aldosterone synthesis.
4. Ontogeny of Aldosterone Secretion
The renin-angiotensin-aldosterone system (RAAS) is known
to be active by around 16 weeks of gestational age [16]. In
the neonatal period a relative state of aldosterone resistance
exists.Inextremeprematurityaldosteroneconcentrationcan
be as high as 12–29,000pmol/L [17]. In term neonates the
average concentration of aldosterone is 22,000pmol/L [18]
(upper limit of normal range in adult is 970pmol/L [17]).
During the ﬁrst year of age, there is a steep, progressive
decline in aldosterone to prepubertal concentrations [19].
The physiological basis for the relative aldosterone resistance
in the neonatal period is unclear. Renal tubular immaturity
leading to sodium loss could trigger the activation of RAAS
alternatively impaired ability of renal tubules to respond to
aldosterone action may constitute a protective mechanism
against the high plasma concentration of aldosterone [18].
It is not uncommon in CAH to encounter a normal or
even higher concentration of aldosterone in neonates (com-
pared to childhood range) due to physiological resistance
and possible assay interference from circulating steroids.
The clue to diagnosis in these situations is the rising
plasma potassium concentration which precedes the onset
of hyponatremia around day 7–10 of postnatal life. These
changes are associated with an increase in plasma renin
activity and if left unchecked the development of a salt-
losing crisis. In a recent study in healthy term neonates
Martinerie et al. documented a poor correlation of serum
aldosterone with serum potassium while urinary aldosterone
appeared to perform better. These data if replicated suggest
that spot urinary measurement of aldosterone/creatinine
concentrationalongwithplasmaandurineelectrolytescould
be a more sensitive and better index for evaluation of
mineralocorticoid eﬀector mechanisms [18].
5. Management of Salt Loss in CAH
Most of the patients with aldosterone deﬁciency present
in early infancy with salt loss which can be fatal if not
identiﬁedandtreatedearly.Saltlosscrisesclassicallymanifest
at the end of the ﬁrst week of life. In girls the ambiguity
of the genitalia alerts the clinician to a diagnosis of CAH
and associated aldosterone deﬁciency. Male infants present
with increasing virilization and increased pigmentation of
scrotum but this can be diﬃcult to identify in early infancy
which raises the chance that the actual initial presentation
will be with a salt-losing crisis. Not all infants present with
a salt-losing crisis and failure to thrive is another form of
presentation.
Aldosterone deﬁciency results in excessive sodium and
insuﬃcient potassium excretion in the urine which results
in hyperkalemia, hyponatremia, hypovolemia, and hyper-
reninemia. Cortisol deﬁciency in these patients contributes
to hypoglycemia, poor cardiac function, poor vascularInternational Journal of Pediatric Endocrinology 3
responsetocatecholamines,adecreasedglomerularﬁltration
rate, and increased secretion of antidiuretic hormone [20].
Cortisol and aldosterone deﬁciency together cause hypona-
tremic dehydration and shock. Shock is further exacerbated
bythedeﬁciencyofcatecholamineswhichoftenaccompanies
salt-losing CAH [13].
The acute circulatory collapse needs intravenous resusci-
tation with normal saline, glucose, and intravenous hydro-
cortisone. In females with ambiguous genitalia and males
with a family history of CAH the acute salt-losing state can
be avoided by daily monitoring of the serum electrolyte
concentrations in the neonatal period. The ﬁrst change is
an increase in the serum potassium concentration above
5.5mmol/L and this may be associated with a serum sodium
concentration in the lower quartile of the normal range
or actual hyponatremia. At this point blood should be
drawn for the measurement of aldosterone and plasma renin
activity.
Treatment will probably be already ongoing with oral
hydrocortisone (10–12mg/m2/day, ∼3–4.5mg/day) and 9α-
ﬂudrocortisone (150μg/m2/day, ∼50μg/day) with sodium
supplements of up to 10–12mmol/Kg/day (Sodium 1mmol
= 1mEq) should be introduced. If a salt-losing crisis does
not manifest in the 7–10 days of life, ongoing monitoring
with twice weekly electrolytes and weekly measures of weight
should be undertaken out to about 6–8 weeks of life.
Salt supplementation is required during infancy as the
daily intake of milk (breast or milk formula) provides only
2mmol/kg/day of sodium which is insuﬃcient to replace
the sodium deﬁcit that arises in CAH. Unless there is
adequate replacement of sodium simply increasing the dose
of 9α-ﬂudrocortisone will not normalize the serum sodium.
Some clinicians use higher doses of 9α-ﬂudrocortisone up
to 350μg/day [21] but the authors ﬁnd that in the majority
of cases a 9α-ﬂudrocortisone dose of 150μg/m2/day (∼
50μg/day) with salt supplements of 5–8mmol/kg/day is
suﬃcient.Intheeventofpersistenthyponatremiadoseof9α-
ﬂudrocortisone is increased only after 10–12mmol/kg/day
of sodium supplements have failed to normalize the serum
sodium. Care needs to be taken with high doses of 9α-
ﬂudrocortisone as the medication has dexamethasone like
glucocorticoid potency and any dose of 9α-ﬂudrocortisone
needs to be factored into the calculation of the total
glucocorticoid daily dose. Once the serum sodium nor-
malizes monitoring of serum electrolytes, blood pressure is
requiredtotitratethedoseofsodiumand9α-ﬂudrocortisone
supplements.Onceweaningisfullyestablished,byaround6–
8 months of age, salt supplements are generally not required.
The dose of 9α-ﬂudrocortisone during the ﬁrst and
second years of life in CAH is higher than that at other stages
of life. At the point of the salt-losing crisis the requirement
fora higher dose of 9α-ﬂudrocortisone probablyresultsfrom
the anti-aldosterone nature of the precursors accumulated
in 21-hydroxylase deﬁciency [22]. As the child grows, a
maximum dose of 100μg/day is usually suﬃcient and in
adolescentandadults50–100μg/dayistheusualrequirement
[23].
The half life of aldosterone is relatively short; however
9α-ﬂudrocortisone has a longer duration of action and can
usually be administered once a day although twice daily
therapywithtwoequallydivideddosesispracticed[21].This
can be especially valuable approach in situations of increased
physiological loss of ﬂuid and electrolytes, for example, heat,
when patients may require higher and more frequent doses
of 9α-ﬂudrocortisone [24].
CAH and its management is complicated by obesity,
insulin resistance [25–27], and elevated 24-hour ambulatory
arterial blood pressure measurements with absence of the
nocturnal dip in blood pressure [28]. These complications
place patients at signiﬁcant risk for developing metabolic
syndrome-related atherosclerotic cardiovascular disease in
adult life [28]. For future cardiovascular health it is of
paramount importance to keep the serum electrolytes and
blood pressure within the normal range with the right
balance of sodium supplements and 9α-ﬂudrocortisone
replacement. Overtreatment can lead to hypertension which
can go unnoticed as children largely remain asymptomatic.
With dexamethasone-like glucocorticoid potency of 9α-
ﬂudrocortisone, overtreatment can also impact on growth
and body composition and impart insulin resistance. During
the ﬁrst year of life treatment with 9α-ﬂudrocortisone is
monitored by measurement of serum electrolytes along with
blood pressure every 2-3 months. During the second year
of life monitoring of treatment can be performed every 6
months followed by yearly in childhood and adolescence.
Forthedoseatwhich9α-ﬂudrocortisoneisadministered,
drug interactions are minimal. However, caution must be
taken when it is concomitantly used with antihypertensives
especially those which act through RAAS pathway. 9α-
ﬂudrocortisone can potentiate the hypokalemic eﬀects of
sympathomimetics, Beta2 agonist, and theophylline espe-
cially when used with IV hydrocortisone in patients with
acute severe asthma.
Theneedforextramineralocorticoidreplacementduring
stress and elective surgery is unclear. Where oral intake
is possible 9α-ﬂudrocortisone should be administered. If
oral intake is not possible, the doses of intravenous hydro-
cortisone recommended for stressful conditions [23]o f t e n
circumvent the need for 9α-ﬂudrocortisone as the mineralo-
corticoid potency of 20mg hydrocortisone is equivalent to
50μgo f9 α-ﬂudrocortisone. Regular monitoring of serum
and urine electrolytes should be undertaken with adequate
intravenous substitution of sodium. Oral 9α-ﬂudrocortisone
should be commenced as soon as oral intake is feasible and
gastrointestinal absorption is deemed possible.
6. Summary:Practice Points
(1) Approximately 75%–80% of patients with CAH fail
to synthesize suﬃcient aldosterone to maintain salt
balance.
(2) Early recognition and replacement with 9α-
ﬂudrocortisone and salt supplements will prevent
development of potentially lethal salt losing crises.
(3) Salt supplementation is generally not required after
weaning is started.4 International Journal of Pediatric Endocrinology
(4) Dose of aldosterone is traditionally calculated based
on body surface area and is higher during infancy
compared to childhood and adults.
(5) Regular monitoring of blood pressure and measure-
ment of plasma electrolytes and renin are required to
prevent complications of under or over dosage.
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